Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association

Robert A. Gabbay,Debbie Kendall,Christine Beebe,John Cuddeback,Todd Hobbs,Naeem D. Khan,Sandra Leal,Eden Miller,Lucia M. Novak,Swapnil N. Rajpathak,Paul Scribner,Luigi Meneghini,Kamlesh Khunti
DOI: https://doi.org/10.2337/cd20-0053
2020-10-01
Clinical Diabetes
Abstract:Research has shown that getting to glycemic targets early on leads to better outcomes in people with type 2 diabetes; yet, there has been no improvement in the attainment of A1C targets in the past decade. One reason is therapeutic inertia: the lack of timely adjustment to the treatment regimen when a person’s therapeutic targets are not met. This article describes the scope and priorities of the American Diabetes Association’s 3-year Overcoming Therapeutic Inertia Initiative. Its planned activities include publishing a systematic review and meta-analysis of approaches to reducing therapeutic inertia, developing a registry of effective strategies, launching clinician awareness and education campaigns, leveraging electronic health record and clinical decision-support tools, influencing payer policies, and potentially executing pragmatic research to test promising interventions.
English Else
What problem does this paper attempt to address?